Director US Health Economic Value Access & Strategy (HEVAS)

Benefits

Parental leave

Not verified

Non-birth-parent leave

Not verified

Family-building benefits

• Fertility benefits: Not verified
• Adoption assistance: Not verified
• Surrogacy assistance: Not verified

Mental health support

Not verified

Relocation assistance

Not verified

Childcare support

Not verified

Learning budget

Not verified

Verification

Not verified checked Jun 13, 2026

Salary

$240K-$265K From the posting source checked Jun 20, 2026

401(k) match

Reported from DOL Form 5500 industry filing (not employer-specific)

Was this benefit information wrong? Tell us.

Market context

U.S. role benchmark (BLS OEWS)

$61,842 U.S. median for this role

Projected growth (BLS Employment Projections)

+1.9% - Slower

U.S. benchmark only; posted salary is not compared across countries or currencies.

Matched to SOC 11-1021 - Operations aggregate by role bucket.

Source: U.S. Bureau of Labor Statistics, OEWS, May 2024 and Employment Projections, 2024-2034.

Role

Role function

Operations From the posting source checked Jun 20, 2026

Seniority

Director Plus From the posting source checked Jun 20, 2026

Work mode

Remote From the posting source checked Jun 20, 2026

In-office days

0 days From the posting source checked Jun 20, 2026

Schedule

Shift type

Not verified

Weekend work

Not verified

Company

Company stage

Public-company From the posting source checked Jun 20, 2026

Equity

Offered Verified - SEC 10-K source checked Jun 20, 2026

Application

Cover letter

Not verified

Assessment

Not verified

Deadline

Not stated

Where they hire

State eligibility is not yet verified.

About this role

Director US Health Economic Value Access & Strategy (HEVAS) Remote Iovance Biotherapeutics aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapy for people with cancer. We are pioneering a transformational approach to treating cancer by harnessing the ability of the human immune system to recognize and attack diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, which may be a promising option for patients with cancer. Overview In the US Cell & Gene (CGT) Marketplace, the payer is not only our Commercial and Government Health Plans, but also the Formulary Decision Makers within our Authorized Treatment Centers (ATCs) who are evaluating the financial viability of our therapies against all other Cell & Gene therapies (CGTs). Iovance is seeking Health Economic Value Access and Strategy (HEVAS) Director as a part of the US Market Access function to develop and translate economic evidence into value-based messaging and will be responsible for developing payer resources, billing & coding guides and patient support in alignment with our value proposition. This individual will understand Payer, hospital and provider clinic evaluation and financial feasibility to support the US Payer field team with pre-approval market readiness (FDAMA 114), cost of care / site of care and cost-effectiveness for our key formulary decision makers. This Market Access leader will partner cross-functionally to identify pricing strategies for our approved

Read the full description at job-boards.greenhouse.io. FewerJobs shows a preview and links to the original posting.